Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

Last updated: June 5, 2024
Sponsor: ANRS, Emerging Infectious Diseases
Overall Status: Active - Recruiting

Phase

3

Condition

Hiv/aids

Hiv Infections

Aids And Aids Related Infections

Treatment

TDF/FTC 300mg/200mg fixed-dose combination tablets

TAF/FTC 25mg/200mg fixed-dose combination tablets

Clinical Study ID

NCT05813964
ANRS 0029s
2022-502931-20
  • Ages > 18
  • Male
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the efficacy, acceptability, and safety of a simplified event-driven pre-exposure prophylaxis of HIV based on oral TAF/FTC in HIV-uninfected cisgender men who have sex with men (MSM).

Primary objective: To assess the efficacy of emtricitabine 200 mg + tenofovir alafenamide 25 mg (F/TAF), taken 2 to 24 hours before sexual intercourse followed by a second dose 24 hours after the first intake, in reducing the risk of HIV acquisition in MSM relative to the background HIV incidence rate.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male at birth age ≥ 18 years old

  • Reporting having sex with men

  • Negative 4th generation HIV-1 and HIV-2 test

  • Reporting condomless anal sex with men not more often than two days during the previous month and able to plan their sexual activity

  • Risk of HIV acquisition based on self-report of at least one of the following behaviors during the 6 months before enrollment: condomless anal sex with at least 2 different sexual partners, sexually transmitted infection (rectal chlamydia and/or rectal gonorrhea and/or syphilis), provided or received money goods or favor in exchange of sex, binge drinking or use of non-injectable recreational drugs.

  • Consenting to participate and agreeing to follow the clinical trial procedures, including adherence to study visits every 3 months

  • In France: Person affiliated with or benefiting from a social security system (article L1121-11of the public health code in France)

Non-inclusion criteria:

  • Women and trans women

  • Taking feminizing hormone therapy

  • Positive HIV test result at screening or enrollment even if HIV infection is not confirmed

  • Positive hepatitis B surface antigen test

  • ALT or AST > 4 ULN

  • Estimated glomerular filtration rate < 60mL/min/1.73m²

  • History of chronic kidney disease, osteoporosis, osteopenia or pathological fracture not related to trauma

  • Hypersensitivity to the study products F/TDF or F/TAF

  • Past or concurrent participation in a HIV vaccine trial or concurrent participation in another clinical trial without the agreement of the principal investigators of the two trials

  • Use of intravenous drugs within the last 12 months

  • Person under legal guardianship

  • Not likely to comply with the clinical trial procedures or with any condition incompatible with study participation, upon the investigator's judgement.

  • Ongoing Post-Exposure Prophylaxis (PEP) for HIV

Study Design

Total Participants: 524
Treatment Group(s): 2
Primary Treatment: TDF/FTC 300mg/200mg fixed-dose combination tablets
Phase: 3
Study Start date:
June 05, 2024
Estimated Completion Date:
May 31, 2027

Study Description

The study will enroll HIV-uninfected MSM at risk for acquiring HIV infection. Participants will be enrolled over 2 years and followed up until the closure of the clinical study. Therefore, the follow up duration will be up to 3 years for first enrollees and up to1 year for the last enrollee. The study will be implemented in Thailand (60% of participants) and France (40%).

Participants will be randomly assigned to one of two regimens:

  • Experimental Arm (F/TAF): one tablet of the fixed-dose combination of emtricitabine (FTC) 200 mg + tenofovir alafenamide (TAF) 25mg, 2 to 24 hours before sexual intercourse followed by a second tablet 24 hours after the first intake.

  • Control Arm (F/TDF): two tablets of the fixed-dose combination of emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg, 2 to 24 hours before sexual intercourse followed by a third tablet 24 hours after the first drug intake and a fourth tablet 24 hours later.

Participants will attend up to 15 study visits throughout the study. Visits may include physical examinations, blood collection, urine collection, and swabs collection (oral and rectal). At the end of their study participation, all participants will be transitioned to locally available HIV prevention services, including PrEP.

Connect with a study center

  • AP-HP - Hôpital Saint-Louis

    Paris,
    France

    Site Not Available

  • STIs Clinic of the Office of Disease Prevention and Control Region 1

    Chiang Mai,
    Thailand

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.